Judith M. Matthews - 31 Mar 2023 Form 4 Insider Report for Iterum Therapeutics plc (ITRM)

Reporting relationship: Chief Financial Officer
Issuer ticker: ITRM
Reported as of: 31 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2023, 20:00:18 UTC
Prior SEC filing: 14 Mar 2023
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Judith M. Matthews

Key filing fact

Judith M. Matthews filed Form 4 for Iterum Therapeutics plc (ITRM) on 03 Apr 2023.

Key facts

This page summarizes Judith M. Matthews's Form 4 filing for Iterum Therapeutics plc (ITRM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2023, 20:00.

Change

Previous filing in this sequence was filed on 14 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITRM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 31 Mar 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 100,000
Exercise price: $1.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest at a rate of 33.3% of the total number of shares on the one-year anniversary of March 31, 2023 and the remaining 66.7% will vest in equal monthly installments thereafter until March 31, 2026, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.